An open, multi-center, randomized, controlled, non-inferiority clinical trial of simplified left atrial appendage occlusion planned by CT artificial intelligence software

INTERVENTION: CT group:preprocedural Cardiac CTA, introprocedural DSA, postprocedural Cardiac CTA, undergo Cardiac CTA 3 & 12 month after LAAO;Control group:preprocedural Cardiac CTA, intraprocedural transesophageal echocardiography, postprocedural Cardiac CTA, undergo Cardiac CTA 3 & 12 month after LAAO; CONDITION: Non‐valvular atrial fibrillation PRIMARY OUTCOME: Incidence of peridevice leak;Severe pericardial effusion;Total procedural duration;Measurement of Peri‐device leak; SECONDARY OUTCOME: Compression rate;Endothelialization;Procedural complications, such as air‐embolism, cardiac valve injury, cardiac arrest etc.;Composite occurrence of all‐cause death, stroke major adverse cardiovascularand cerebrovascular events (MACCE);Procedural manipulatory duration;Contrast Volume;Device Consumption;Device‐related thrombus;Hospitalization Time;Atrial septal puncture times;Occluder Retrieved Times; INCLUSION CRITERIA: (1) Age=18 yrs; (2) Paroxysmal, persistent or permanent nonvalvular atrial fibrillation; (3) CHA2DS2‐VASc score = 2 for males and = 3 for females (C: congestive heart failure=1, H: hypertension=1, A: age = 75 years=2, D: diabetes=1, S: previous stroke / TIA/ thromboembolism history=2, V: vascular disease=1, A: age 65‐74 years=1, Sc: female=1); (4) Oral anticoagulation contraindication or HAS‐BLED score = 3 (1 score for any of the following items: hypertension with systolic blood pressure higher than 160mmHg, abnormal liver function, abnormal renal function, including lacunar stroke, history of hemorrhage or bleeding tendency, unstable international standard ratio, age > 65 years old, use of antiplatelet or non‐steroidal anti‐inflammatory drugs, alcohol overdose).